S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
NASDAQ:ACCD

Accolade (ACCD) Stock Price, News & Analysis

$10.47
+0.48 (+4.80%)
(As of 11:54 AM ET)
Today's Range
$9.94
$10.51
50-Day Range
$9.22
$13.92
52-Week Range
$6.33
$17.00
Volume
195,673 shs
Average Volume
741,740 shs
Market Capitalization
$810.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67

Accolade MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
56.8% Upside
$15.67 Price Target
Short Interest
Healthy
3.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
-0.30mentions of Accolade in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$953,666 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.38) to ($1.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.62 out of 5 stars

Business Services Sector

23rd out of 313 stocks

Business Services, Not Elsewhere Classified Industry

12th out of 91 stocks

ACCD stock logo

About Accolade Stock (NASDAQ:ACCD)

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ACCD Stock Price History

ACCD Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
ACCD Apr 2024 10.000 call
ACCD Apr 2024 12.500 call
Accolade Inc.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Accolade To Present at Upcoming Investor Conferences
Accolade Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Accolade Stock (NASDAQ:ACCD), Short Interest Report
PLTR Mar 2024 12.000 put
Accolade Welcomes Kindbody to Trusted Partner Ecosystem
Why Accolade (ACCD) Stock Might be a Great Pick
Accolade assumed with Neutral from Buy at DA Davidson
See More Headlines
Receive ACCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/08/2024
Today
3/28/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
2/28/2025

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:ACCD
Fax
N/A
Employees
2,370
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.67
High Stock Price Target
$19.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+56.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

Net Income
$-459,650,000.00
Pretax Margin
-31.48%

Debt

Sales & Book Value

Annual Sales
$388.49 million
Book Value
$6.51 per share

Miscellaneous

Free Float
70,983,000
Market Cap
$773.31 million
Optionable
Optionable
Beta
2.08
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Rajeev Singh (Age 56)
    Chairman of the Board & CEO
    Comp: $778.5k
  • Mr. Robert Cavanaugh (Age 55)
    President
    Comp: $582.63k
  • Mr. Stephen H. Barnes CPA (Age 52)
    CFO & Treasurer
    Comp: $557.5k
  • Ms. Kristen Bruzek
    Senior Vice President of Operations
  • Mr. Colin McHugh (Age 45)
    Chief Accounting Officer
  • Mr. Todd Friedman
    Senior Vice President of Investor Relations
  • Mr. Richard Eskew (Age 49)
    Executive VP, General Counsel, CCO & Secretary
  • Ms. Jennifer Hanson
    Executive VP & Chief Human Resource Officer
  • Mr. Drew Garner
    Executive Vice President of Engineering
  • Dr. Shantanu Nundy M.B.A.
    M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory Board

ACCD Stock Analysis - Frequently Asked Questions

Should I buy or sell Accolade stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares.
View ACCD analyst ratings
or view top-rated stocks.

What is Accolade's stock price target for 2024?

16 equities research analysts have issued 12-month price targets for Accolade's shares. Their ACCD share price targets range from $12.00 to $19.00. On average, they anticipate the company's stock price to reach $15.67 in the next year. This suggests a possible upside of 56.8% from the stock's current price.
View analysts price targets for ACCD
or view top-rated stocks among Wall Street analysts.

How have ACCD shares performed in 2024?

Accolade's stock was trading at $12.01 at the beginning of the year. Since then, ACCD shares have decreased by 16.8% and is now trading at $9.99.
View the best growth stocks for 2024 here
.

Are investors shorting Accolade?

Accolade saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,780,000 shares, an increase of 15.4% from the February 29th total of 2,410,000 shares. Based on an average trading volume of 746,700 shares, the short-interest ratio is currently 3.7 days.
View Accolade's Short Interest
.

When is Accolade's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our ACCD earnings forecast
.

How were Accolade's earnings last quarter?

Accolade, Inc. (NASDAQ:ACCD) announced its earnings results on Monday, January, 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.17. The company had revenue of $99.37 million for the quarter, compared to the consensus estimate of $96.16 million. Accolade had a negative trailing twelve-month return on equity of 27.27% and a negative net margin of 31.59%. Accolade's quarterly revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.56) EPS.

What guidance has Accolade issued on next quarter's earnings?

Accolade updated its fourth quarter 2024 earnings guidance on Monday, January, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $121.5 million-$125.5 million, compared to the consensus revenue estimate of $126.3 million.

What is Rajeev Singh's approval rating as Accolade's CEO?

152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Accolade own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).

When did Accolade IPO?

Accolade (ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

Who are Accolade's major shareholders?

Accolade's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (8.79%), Brown Advisory Inc. (7.70%), Vanguard Group Inc. (6.88%), Vanguard Group Inc. (6.88%), Bellevue Group AG (5.82%) and Dimensional Fund Advisors LP (2.48%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh and Stephen H Barnes.
View institutional ownership trends
.

How do I buy shares of Accolade?

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACCD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners